Ornithine phenylacetate - Yaqrit
Alternative Names: IV L-ornithine phenylacetate; L-Ornithine phenylacetate; MNK 6106; MNK-6105; OCR-002; OP; oral L-ornithine phenylacetate; Ornithine hydrochloride/sodium phenylacetate; Sodium phenylacetate/ornithine hydrochloride; UCL-L1V; YAQ006; YAQ007Latest Information Update: 15 May 2025
At a glance
- Originator University College London
- Developer Ocera Therapeutics
- Class Basic amino acids; Diamino amino acids; Esters; Hepatoprotectants; Neuroprotectants; Phenylacetates; Small molecules
- Mechanism of Action Aminohydrolase modulators; Ammonia scavengers; NF-kappa B modulators; Nitric oxide synthase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Hepatic encephalopathy
- Phase II Liver cirrhosis; Liver failure
- No development reported Non-alcoholic fatty liver disease